

Characterization of Two Eurofins DiscoverX's PrecisION[®] Nicotinic Cell Lines Using Automated Electrophysiology

Drug Discovery for Ion Channels XXIII Satellite Meeting February 17th, 2023

James Costantin, Ph.D. Scientific Market Development Manager – Ion Channels Eurofins DiscoverX, Fremont CA



OUR EXPERTISE IN YOUR HANDS. DISCOVER CONFIDENTLY. Agenda

eurofins DiscoverX

The Eurofins Discovery PRODUCTS COMPANY

Eurofins DiscoverX company introduction Introduction to ion channel products

- PrecisION[®] stable cell lines
- PathHunter[®] cell-based trafficking assays
- Custom development capabilities
- SyncroPatch 384i utility in workflows
- Nicotinic data on SyncroPatch
- Summary and conclusions




Eurofins DiscoverX

Construction Structure Company The Eurofins Discovery PRODUCTS COMPANY

Technology based on the Enzyme Fragment Complementation (EFC) platform

• Flexible assay platform based on a split β-galactosidase enzyme



Over 1000 functional assays available for popular target classes

- GPCRs
- Kinases
- Cytokines
- Checkpoints Receptors
- Nuclear Proteins
- Epigenetic Proteins
- Cell Signaling Pathway Targets
- Ion Channels



Headquarters based in Fremont, CA



High-quality cell lines for target discovery, hit screening, lead optimization, and safety studies

Eurofins acquired DiscoverX (founded in 2000) in 2017 and became part of Eurofins Discovery


Obtained PrecisION ion channel stable cell lines portfolio through acquisitions

- Cytomyx begins the collection of PrecisION cell lines
- Serologicals acquires Cytomyx
- Millipore acquires Serologicals
- Merck KGaA acquires Millipore
- Eurofins acquires Merck Millipore (EMD Millipore)

Eurofins DiscoverX PrecisION® Channel Cell Lines


eurofins

The Eurofins Discovery PRODUCTS COMPANY






- Identify pharmacochaperones that rescue disease relevant mutant membrane proteins
- Currently two ion channel trafficking assays
 - Contact <u>customdevelopment@eurofins.com</u> for additional assays
- CFTR-ΔF508 trafficking assay (collaboration with Vertex)
 - Compound rank order of correctors was the same as indicated in the literature
 - Additive effect was revealed for VS-809 and C4 corrector



CFTR-∆F508	Cystic fibrosis transmembrane conductance regulator	Cystic fibrosis
KCNH2(G601S)	Potassium voltage-gated channel, subfamily H (eag-related), member 2	Long QT syndrome (Cardiac arrhythmias)



Custom Development Capabilities




The Eurofins Discovery PRODUCTS COMPANY



- Development Expertise Decades of cell-based assay development, cell line engineering, and recombinant enzyme development expertise
- Cell Line Engineering Capability Exogenous expression approaches (constitutive vs inducible) or gene editing (e.g. KO/KI with CRISPR/Cas9)
- Collaborative Consultative assay development with regular updates through a dedicated project manager
- Complete Solution Customized assay development with screening and profiling services within the same team

Custom Development Capabilities



Agenda


eurofins DiscoverX

The Eurofins Discovery PRODUCTS COMPANY

Eurofins DiscoverX company introduction Introduction to ion channel products

- PrecisION[®] stable cell lines
- PathHunter[®] cell-based trafficking assays
- Custom development capabilities


SyncroPatch 384i utility in workflows Nicotinic data on SyncroPatch Summary and conclusions



Cell line production, marketing, and technical support

- Quality Control (QC) production of existing Eurofins
 DiscoverX PrecisION[®] cell lines at Fremont, CA site
- QC production of frozen ready-to-use (RTU) PrecisION channel cell lines and "panels" for therapeutic areas
- Validation of custom ion channel targets through Custom Development Capabilities program
- Expansion of our Custom Development Capabilities program into rare disease targets
 - Channelopathy variants and wild type controls

Ion channel CRO Services performed by Eurofins Discovery in St. Charles, MO







The Eurofins Discovery PRODUCTS COMPANY



First run (no optimization)

- Low seals
 - 40% over 500M
- Nice expression
 - 86% < -200 pA
- All SP 384i data (except where noted)
 - Single shot addition, ligand-puff
 - Single-hole/well plate




SyncroPatch (SP) 384i Data, Sept 16th 2022

eurofins DiscoverX

The Eurofins Discovery PRODUCTS COMPANY

Previous work on this cell line showed the effect of the PAM LY2087101 in the presence of 5 μM ACh (~EC_{20})

- Large potentiation by 3 µM LY2087101
- Inhibition at higher concentrations




Source: Data Sheet for CYL3106 – PatchXpress® Data **Reference:** Broad LM *et al* (2006). JPET 318(3):1108-1117.

Positive Allosteric Modulation (PAM) of nAChR $\alpha 4/\beta 2$



DiscoverX


The Eurofins Discovery PRODUCTS COMPANY





The Eurofins Discovery PRODUCTS COMPANY

Robust enhancement of submaximal ACh currents (EC₂₀) by LY2087101




SyncroPatch 384i Data, Nov 02, 2022 (#3)



Previous work on this cell line showed the effect of the antagonist dihydro- β -erythroidine (DH- β E) in the presence of 100 μ M Ach

• Large Inhibition by 10 μM DH-βE



Source: Data Sheet CYL3106 – PatchXpress® Data **References:**


- Chavez-Noriega LE et al (1997), JPET 280(1): 346-356
- Yu R et al (2019). Br J Pharmacol. 2019;176:2750–2763

Antagonist* Data for nAChR $\alpha 4/\beta 2$




DiscoverX

The Eurofins Discovery PRODUCTS COMPANY






Complete inhibition of ACh currents down to the baseline noise





SyncroPatch 384i Data, Nov 08, 2022

Functional Activity

- Agonist Activation: Currents were activated by 200 μM ACh, and partially activated with 5 μM ACh [EC₂₀]. PAM enhancement by 2.4 fold of the 5 μM ACh currents with 3 μM LY2087101
- Antagonist Inhibition: Inhibition by 10 μ M dihydro- β -erythroidine (DH- β E) of currents activated by 100 μ M ACh












First Run (no optimization)

- Good Seals
 - 95.8% over 500M
- Nice Expression
 - 86% < -75pA
 - 76% < -100 pA




SyncroPatch 384i Data, Oct 11, 2022




Construction Const

Previous work on this cell line showed the effect of the PAM PNU-120596 in the presence of 300 μM ACh

• Large potentiation by PNU-120596





Source: Data Sheet CYL3097 – PatchXpress® Data **Reference:** Hurst RS et al (2005), J Neurosci., 25(17): 4396 – 4405

Positive Allosteric Modulation (PAM) of nAChR α7/ric3



DiscoverX

The Eurofins Discovery PRODUCTS COMPANY




Positive Allosteric Modulation (PAM) of nAChR α7/ric3



DiscoverX

The Eurofins Discovery PRODUCTS COMPANY



Drug Discovery & Development Phase-Appropriate Solutions | Our Expertise in Your Hands – Discover Confidently

100k


Positive Allosteric Modulation (PAM) of nAChR α7/ric3



DiscoverX

The Eurofins Discovery PRODUCTS COMPANY

5 µM PNU-120596 potentiates ACh currents by over 30 fold



Antagonist* Dose Response Curve of nAChR α7/ric3


🔅 eurofins

DiscoverX

The Eurofins Discovery **PRODUCTS COMPANY**

Plate view of MLA dose response

- Fixed Y-scaling (no-autoscaling)
- 8-hole Population Chip






Drug Discovery & Development Phase-Appropriate Solutions | Our Expertise in Your Hands – Discover Confidently

Antagonist* Dose Response Curve of nAChR α7/ric3


The Eurofins Discovery PRODUCTS COMPANY

eurofins



Functional Activity

- Agonist Activation: Currents were activated by 300 μM ACh. The 300 μM ACh currents were enhanced with the PAM 5 μM PNU-120596
- Antagonist Dose Response Curve: MLA dose response curves measured using 8-hole/well plates in the absence of within well normalization (single shot 384-pipette addition)



Summary and Conclusions


Our cell production team is actively expanding and re-validating our master cell banks into working cell bank (product) stocks in Fremont, CA. We are also providing Technical Support for our current product portfolio of PrecisION[®] stable cell lines out of our Fremont office

We look forward to supporting your ion channel cell line needs!

The Custom Development Capabilities program is available for exclusive or nonexclusive development of new ion channel targets

We strongly encourage new requests to our Custom Development Capabilities program, especially for channelopathy variants, and corresponding wild-type ion channels

 This is an exciting rapidly expanding field of research and do hope to be directly involved in helping develop therapeutics toward channelopathies by providing stable cell lines and ion channel trafficking assays



Visit <u>discoverx.com/ion-</u> <u>channels</u> to learn more